Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Pharmacogenomics in Cardiovascular Therapeutics. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 1: Which among the following is the false statement regarding statins?
- A. These drugs should not be stopped even in severe conditions like injury, surgery etc.
- B. Although HMG-CoA reductase inhibitors substantially reduce the risk of cardiovascular events, there is mild increase in lipoprotein a (Lpa) levels.
- C. With the long term use, there is slight increase in the incidence of type 2 diabetes mellitus.
- D. They can be given with verapamil and other enzyme inhibitors (Correct Answer)
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***They can be given with verapamil and other enzyme inhibitors***
- This statement is **FALSE** and is the correct answer because **verapamil** (a moderate CYP3A4 inhibitor) and other potent CYP3A4 inhibitors like **clarithromycin** or **azole antifungals** can significantly increase statin concentrations, raising the risk of adverse effects like **myopathy** and **rhabdomyolysis**.
- **Co-administration** of statins with these inhibitors generally requires careful dose adjustments or avoidance, as they increase the systemic exposure to most statins (especially **simvastatin**, **atorvastatin**, and **lovastatin**).
*These drugs should not be stopped even in severe conditions like injury, surgery etc.*
- This statement could be considered false in certain contexts, as statins **can be temporarily held** in acute, severe conditions like sepsis, major trauma, or complex surgery, especially if there's a concern for **acute kidney injury** or **rhabdomyolysis** [1].
- However, in most routine surgical situations, statins are typically continued due to their cardiovascular protective effects.
*Although HMG-CoA reductase inhibitors substantially reduce the risk of cardiovascular events, there is mild increase in lipoprotein a (Lpa) levels.*
- This statement is **TRUE**. Statins are associated with a **modest increase in Lp(a) levels** (approximately 10-20%), which has been consistently demonstrated in clinical studies [2].
- While statins effectively lower **LDL cholesterol**, Lp(a) levels are largely **genetically determined** and may paradoxically increase with statin therapy, though this effect is generally considered clinically insignificant compared to the overall cardiovascular benefits [2].
*With the long term use, there is slight increase in the incidence of type 2 diabetes mellitus.*
- This statement is **TRUE**. Long-term statin use is associated with a **small but statistically significant increase** in the risk of developing **type 2 diabetes mellitus** (approximately 9-12% increased risk), particularly in individuals with pre-existing risk factors like **metabolic syndrome**.
- This risk, however, is generally **outweighed by the cardiovascular benefits** of statin therapy in at-risk patients, making it an acceptable trade-off.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 2: Which of the following is a characteristic of simvastatin?
- A. Specific CYP3A4 substrate with high interaction potential
- B. Derived from fungal metabolite (Correct Answer)
- C. Prodrug requiring hepatic activation
- D. Short half-life requiring evening dosing
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Derived from fungal metabolite***
- **Simvastatin** and lovastatin are **naturally-derived statins** obtained from **fungal metabolites** (*Aspergillus terreus*), distinguishing them from synthetic statins like atorvastatin, rosuvastatin, and pravastatin [2].
- This is the **most distinguishing characteristic** for classification purposes, as it represents the drug's origin and places it in a specific subclass of HMG-CoA reductase inhibitors.
- The discovery of fungal-derived statins led to the development of the entire statin drug class.
*Prodrug requiring hepatic activation*
- While **simvastatin** is a **lactone prodrug** requiring hepatic hydrolysis to its active beta-hydroxy acid form, this is a pharmacokinetic property shared with lovastatin [1].
- This is a characteristic but not the most distinguishing feature for classification.
*Specific CYP3A4 substrate with high interaction potential*
- **Simvastatin** is extensively metabolized by **CYP3A4**, leading to significant drug-drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice).
- While clinically important, many drugs are CYP3A4 substrates, making this less distinctive as a defining characteristic.
*Short half-life requiring evening dosing*
- **Simvastatin** has a **short half-life** (2-3 hours) and is preferably administered in the evening because cholesterol synthesis is highest at night.
- This is a dosing consideration based on pharmacokinetics rather than a fundamental distinguishing characteristic of the drug's identity.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 3: Which of the following is not considered a pharmacogenetic condition?
- A. Adenosine deaminase deficiency (Correct Answer)
- B. Coumarin insensitivity
- C. G6PD deficiency
- D. Malignant hyperthermia
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Adenosine deaminase deficiency***
- **Adenosine deaminase deficiency** (ADA deficiency) is an **autosomal recessive** metabolic disorder causing severe immunodeficiency, primarily affecting gene function rather than drug response.
- While it can be treated with enzyme replacement therapies or gene therapy, it is not primarily characterized by an altered response to standard therapeutic drugs.
*Coumarin insensitivity*
- **Coumarin insensitivity** refers to an individual's reduced response to **warfarin (a coumarin derivative)**, requiring higher doses to achieve effective anticoagulation.
- This is a well-documented **pharmacogenetic condition**, often linked to variations in genes like *CYP2C9* and *VKORC1*.
*G6PD deficiency*
- **Glucose-6-phosphate dehydrogenase (G6PD) deficiency** is an X-linked genetic disorder that can lead to **hemolytic anemia** upon exposure to certain drugs (e.g., antimalarials, sulfonamides, aspirin) and fava beans [1].
- It is a classic example of a **pharmacogenetic condition** where genetic variations dictate drug-induced adverse reactions [1].
*Malignant hyperthermia*
- **Malignant hyperthermia** is a life-threatening, inherited disorder triggered by certain **inhalation anesthetics** (e.g., halothane, isoflurane) and the **depolarizing muscle relaxant succinylcholine**.
- This condition is caused by mutations in genes involved in calcium regulation in muscle cells (e.g., *RYR1*) and is a critical **pharmacogenetic response**.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 4: Effects of beta blockers on the heart are all of the following except:
- A. Decreases duration of systole (Correct Answer)
- B. Decrease in heart rate
- C. May decrease cardiac output initially.
- D. May precipitate heart failure in acute settings.
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Decreases duration of systole***
- Beta-blockers primarily prolong the **duration of systole** by extending the **ejection time** and slowing ventricular relaxation.
- They also increase the **diastolic filling time** by reducing heart rate, impacting overall cardiac cycle duration.
*Decrease in heart rate*
- Beta-blockers block **beta-1 adrenergic receptors** in the heart, leading to a decrease in **sympathetic stimulation** and thus a reduced heart rate.
- This effect is beneficial in conditions like **tachycardia** and **angina**, as it reduces myocardial oxygen demand.
*May decrease cardiac output initially.*
- By reducing heart rate and contractility, beta-blockers can initially decrease **cardiac output**, especially in patients with pre-existing **ventricular dysfunction**.
- This effect is often transient, as chronic use can lead to beneficial remodeling and improved efficiency in some conditions.
*May precipitate heart failure in acute settings.*
- In patients with acutely decompensated heart failure or severe left ventricular dysfunction, beta-blockers can acutely worsen cardiac function due to their **negative inotropic effects**.
- Therefore, beta-blockers are typically initiated cautiously at low doses in stable heart failure patients and are contraindicated in acute decompensation.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 5: The anticoagulant activity of warfarin can be reduced by all of the following except.
- A. Aspirin (Correct Answer)
- B. Rifampin
- C. Vitamin K
- D. Carbamazepine
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Aspirin***
- **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect.
- Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors.
- When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk.
*Carbamazepine*
- **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4).
- By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect.
- Patients on this combination may require higher warfarin doses to maintain therapeutic INR.
*Rifampin*
- **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4).
- It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect.
- This interaction often necessitates substantial increases in warfarin dosage.
*Vitamin K*
- **Vitamin K** is the direct antagonist of warfarin's mechanism of action.
- Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X.
- Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 6: What is the PRIMARY vascular function of PGI2 (prostacyclin)?
- A. Promotes platelet aggregation and causes vasoconstriction
- B. Acts primarily as a bronchoconstrictor
- C. Stimulates inflammatory cell chemotaxis
- D. Inhibits platelet aggregation and causes vasodilation (Correct Answer)
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Inhibits platelet aggregation and causes vasodilation***
- **PGI2 (prostacyclin)** is a potent **vasodilator** that relaxes smooth muscle in blood vessels, increasing blood flow.
- It also effectively **inhibits platelet aggregation**, preventing the formation of blood clots.
*Promotes platelet aggregation and causes vasoconstriction*
- This describes the primary actions of **thromboxane A2 (TXA2)**, not PGI2.
- TXA2 is produced by platelets and plays a key role in **hemostasis** by constricting blood vessels and promoting platelet clumping.
*Acts primarily as a bronchoconstrictor*
- While some prostaglandins can affect bronchial tone, **PGI2's primary vascular role** is vasodilation and anti-aggregation.
- **Leukotrienes** and certain **prostaglandins (e.g., PGD2, PGF2α)** are more classically associated with bronchoconstriction.
*Stimulates inflammatory cell chemotaxis*
- This is primarily a function of other inflammatory mediators such as **leukotriene B4 (LTB4)** and **C5a anaphylatoxin**.
- While other eicosanoids can indirectly influence inflammation, **PGI2's main actions** are vascular and anti-platelet.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 7: A patient with history of ischemic stroke was started on clopidogrel. However, she had another attack of stroke after 6 months. Which of the following is likely to be responsible for the failure of clopidogrel in this patient?
- A. Upregulation of CYP1A1
- B. Downregulation of CYP2E1
- C. Downregulation of CYP2C19 (Correct Answer)
- D. Downregulation of CYP2D6
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Reduced function/Loss of function of CYP2C19***
- **Clopidogrel** is a **prodrug** that requires activation by **hepatic cytochrome P450 (CYP) enzymes**, primarily **CYP2C19**, to its active metabolite.
- **Genetic polymorphisms** causing **reduced function or loss of function of CYP2C19** (e.g., CYP2C19*2, *3 alleles) result in insufficient conversion of clopidogrel to its active form, leading to **clopidogrel resistance** and increased risk of thrombotic events like recurrent stroke.
- These **poor metabolizers** have significantly reduced antiplatelet response to standard clopidogrel doses.
*Upregulation of CYP1A1*
- **CYP1A1** is involved in the metabolism of various xenobiotics but plays a **minimal role** in clopidogrel activation.
- Upregulation of CYP1A1 would not be a primary factor in clopidogrel failure as it is not the main enzyme responsible for its bioactivation.
*Downregulation of CYP2E1*
- **CYP2E1** is primarily involved in the metabolism of small organic molecules, some drugs, and toxins, and has **no significant role** in the bioactivation of clopidogrel.
- Therefore, changes in its expression would not impact clopidogrel's efficacy.
*Downregulation of CYP2D6*
- **CYP2D6** is a major enzyme involved in the metabolism of many psychoactive drugs, beta-blockers, and opioids, but plays only a **minor role** in clopidogrel activation compared to CYP2C19.
- Downregulation of CYP2D6 would not be the primary cause of clopidogrel failure.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 8: Which of the following is non-selective 3rd generation Beta blocker ?
- A. Betaxolol
- B. Celiprolol
- C. Nebivolol
- D. Carvedilol (Correct Answer)
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Carvedilol***
- **Carvedilol** is a **non-selective beta-adrenergic antagonist** (blocks both β1 and β2 receptors) with **additional α1-adrenergic blocking activity**, making it a true **3rd generation beta-blocker**.
- The α1-blockade provides **vasodilatory properties**, reducing peripheral vascular resistance and improving hemodynamics.
- It has favorable effects on lipid metabolism and insulin sensitivity, making it particularly useful in heart failure and hypertension.
- Its non-selective beta-blockade combined with vasodilation distinguishes it from selective 3rd generation agents.
*Betaxolol*
- **Betaxolol** is a **selective β1-adrenergic antagonist** without vasodilatory properties.
- Classified as a **2nd generation beta-blocker** due to its cardioselectivity.
- Primarily used in glaucoma and hypertension but lacks the non-selective profile and additional mechanisms of 3rd generation agents.
*Celiprolol*
- **Celiprolol** is a **β1-selective antagonist** with **β2-agonistic effects** providing vasodilation.
- While classified as 3rd generation due to vasodilatory properties, it is **selective for β1**, not non-selective.
- Its β2-agonism causes peripheral vasodilation but maintains β1-selectivity.
*Nebivolol*
- **Nebivolol** is a highly **selective β1-adrenergic antagonist** with **vasodilatory effects via nitric oxide (NO) release**.
- Classified as 3rd generation due to NO-mediated vasodilation, but it is **β1-selective**, not non-selective.
- The combination of high β1-selectivity and endothelial-mediated vasodilation makes it unique among 3rd generation agents.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 9: What is the mechanism of action of ticagrelor?
- A. P2Y12 receptor antagonist (Correct Answer)
- B. Cox inhibition
- C. Inhibition of thromboxane synthase
- D. GPIIb/IIIa inhibition
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***P2Y12 receptor antagonist***
- **Ticagrelor** is an **oral antiplatelet drug** that reversibly binds to the **P2Y12 ADP receptor** on platelet surfaces.
- By blocking this receptor, it prevents **ADP-mediated platelet activation** and subsequent aggregation, reducing the risk of thrombotic events.
*Cox inhibition*
- **COX inhibitors** like **aspirin** prevent the synthesis of **thromboxane A2**, a powerful platelet aggregator.
- This mechanism is characteristic of **NSAIDs** and **aspirin**, not ticagrelor.
*GPIIB/IIIA inhibition*
- **GPIIb/IIIa inhibitors** (e.g., abciximab, eptifibatide, tirofiban) directly block the final common pathway for platelet aggregation by preventing **fibrinogen binding** to the GPIIb/IIIa receptor.
- While also an antiplatelet mechanism, this is distinct from ticagrelor's action on the P2Y12 receptor.
*Inhibition of thromboxane synthase*
- Inhibition of **thromboxane synthase** would reduce the production of **thromboxane A2**, similar to the effect of COX inhibition.
- This is not the primary mechanism of action for ticagrelor; drugs like **dazoxiben** or **picotamide** act through this pathway.
Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG Question 10: Coronary steal syndrome is associated with
- A. Sevoflurane
- B. Halothane
- C. Isoflurane (Correct Answer)
- D. Desflurane
Pharmacogenomics in Cardiovascular Therapeutics Explanation: ***Isoflurane***
- **Isoflurane** is a potent coronary vasodilator which can cause coronary steal syndrome in patients with existing **coronary artery disease**.
- It preferentially dilates normal coronary arteries, diverting blood flow away from stenotic areas, potentially worsening **myocardial ischemia**.
*Sevoflurane*
- **Sevoflurane** is also a vasodilator but is generally considered to have a lower risk of coronary steal compared to isoflurane.
- Its vasodilatory effects are less pronounced in diseased arteries, making it a safer option for patients with **ischemic heart disease**.
*Halothane*
- **Halothane** is known for myocardial depression and arrhythmias, but its coronary dilating properties are less pronounced and it is infrequently associated with coronary steal.
- It is an older inhalational anesthetic that has largely been replaced due to its side effect profile, including potential **hepatotoxicity**.
*Desflurane*
- **Desflurane** is a potent vasodilator, similar to isoflurane, but it typically causes peripheral vasodilation rather than significant coronary steal.
- Its rapid onset and offset are beneficial, but it can cause **tachycardia** and **hypertension** with rapid increases in concentration.
More Pharmacogenomics in Cardiovascular Therapeutics Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
